Prezista Related Published Studies
Well-designed clinical trials related to Prezista (Darunavir)
96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. [2011.08]
Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers. [2011.06.01]
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. [2011.05]
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. [2011.04.24]
The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. [2011.02]
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. [2010.11]
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. [2010.07]
Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300. [2010.06]
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. [2010.01.16]
Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients. [2010]
Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience. [2010]
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. [2010]
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. [2009.11]
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. [2009.09.10]
Improved bioavailability of darunavir by use of kappa-carrageenan versus microcrystalline cellulose as pelletisation aid. [2009.08]
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. [2008.10.01]
Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. [2008.10.01]
[Darunavir as first-line therapy. The TITAN study] [2008.10]
[Darunavir in treatment-naive patients. The ARTEMIS study] [2008.10]
Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. [2008.08]
Resistance profile of darunavir: combined 24-week results from the POWER trials. [2008.03]
Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. [2008.01]
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. [2007.07.07]
Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. [2007.07]
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA. [2007.05]
Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. [2007.03]
Well-designed clinical trials possibly related to Prezista (Darunavir)
Cost-effectiveness of combination therapy with etravirine in
treatment-experienced adults with HIV-1 infection. [2012]
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. [2011.09]
Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. [2011.07.01]
Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison. [2011.07]
Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. [2011.07]
Management of HIV infection in treatment-naive patients: a review of the most current recommendations. [2011.06.01]
Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials. [2011.04.01]
Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. [2011.01]
Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials. [2010.11]
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. [2010.11]
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials. [2010.11]
Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2. [2010.07]
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. [2010.03.15]
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. [2010]
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. [2009.11.13]
Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. [2009.04]
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. [2008.07.24]
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. [2007.07.07]
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. [2005.06.10]
Other research related to Prezista (Darunavir)
Steady-state pharmacokinetic interactions of darunavir/ritonavir with
lipid-lowering agent rosuvastatin. [2012]
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. [2011.12.15]
Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial. [2011.12.01]
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. [2011.08.24]
Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients. [2011.07]
Steady-State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid-Lowering Agent Rosuvastatin. [2011.06.28]
Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil. [2011.06]
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. [2011]
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and
raltegravir once and twice daily in HIV-infected individuals. [2011]
Effects of tipranavir, darunavir, and ritonavir on platelet function,
coagulation, and fibrinolysis in healthy volunteers. [2011]
The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase
inhibitor S/GSK1349572 in healthy participants. [2011]
Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. [2010.10]
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. [2010.09.24]
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. [2010.09.21]
Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy. [2010.07]
The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants. [2010.05.20]
Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. [2010.05]
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. [2010]
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1
viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. [2010]
Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in
HIV-negative healthy volunteers. [2010]
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy
compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96
week ARTEMIS data. [2010]
Etravirine in combination with darunavir/ritonavir and optimized background
regimen results in suppression of HIV replication in treatment-experienced
patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and
safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week
analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300. [2010]
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. [2009.11.01]
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. [2009.09.24]
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. [2009.08.24]
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study. [2009.07.31]
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. [2009.07.06]
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. [2009.07]
Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. [2009.05]
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. [2009.04]
Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection. [2009.03.17]
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. [2009]
Darunavir: a review of its use in the management of HIV infection in adults. [2009]
Use of darunavir and enfuvirtide in a pregnant woman. [2008.12]
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. [2008.12]
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. [2008.11]
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and -experienced patients. [2008.11]
Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2. [2008.10]
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies.] [2008.10]
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. [2008.09.12]
Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases. [2008.09]
New therapeutic agents in the management of HIV: an overview of darunavir for clinicians. [2008.09]
Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine. [2008.08]
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. [2008.07.31]
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. [2008.07]
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. [2008.04.11]
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. [2008.03.12]
Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center. [2008.03]
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. [2008.02]
Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. [2008]
Effect of Repeated Doses of Darunavir plus Low-Dose Ritonavir on the Pharmacokinetics of Sildenafil in Healthy Male Subjects : Phase I Randomized, Open-Label, Two-Way Crossover Study. [2008]
Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). [2008]
Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. [2008]
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. [2007.12.15]
Pharmacokinetic Interaction Between Darunavir and Saquinavir in HIV-negative Volunteers. [2007.12]
Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. [2007.10.15]
|
